Outcomes in Black patients receiving darolutamide plus ADT for mHSPC

Overall Survival Considerations

Key Themes:

• ARANOTE’s overall survival data are still maturing.
• ARASENS data show a promising trend for survival benefit.
• Competing risks and care access issues complicate survival analysis.
• Treatment completion challenges may impact long-term outcomes.

Key Points for Physicians:

• Although definitive overall survival data are pending, trends appear promising.
• Consider social determinants and access issues that may impact long-term outcomes.
• Address potential barriers to treatment completion.
• Monitor for mature survival data as they become available.

Notable Insights: The complexity of survival analysis highlights the importance of considering factors beyond drug efficacy, particularly access to care and treatment completion, which may disproportionately affect Black patients.

Clinical Significance: Early survival trends appear promising but require longer follow-up and consideration of the broader context of care delivery and social determinants that influence outcomes.